YUN LI

5013 52nd Ave Ct w University Place, WA 98467
Cell Phone: 770-542-9813
Email:aiyely8625@gmail.com

EDUCATION:

Master Science of Clinical Research
Morehouse School of Medicine, Atlanta GA 01/2015-05/2016

Bachelor of Medicine in Nursing Science,
Central South University Xiangya School of Medicine Changsha, Hunan, China08/2004-06/2009

LICENSES AND CERTIFICATION:

Registered Nursing License (No. 60657139)
Washington State Board of Registered Nursing, USA 05/2016-Present

Registered Nursing License (No.637683)
New York State Board of Registered Nursing, US 01/ 2010-Present

Identification and Reporting of Child Abuse in NYS
New York State Nurses Association 06/2010-Present

BLS Certification: First Aid with CPR and AED(No.SCIFBDA1B5657B4)
American Heart Association USA 01/2011- Present

HIPAA Compliance Training
Morehouse School of Medicine 04/2014-Present

Introduction to the Principles and Practice of Clinical Research
The National Institutes of Health Clinical Center 04/2014-Present

Biomedical Responsible Conduct of Research
Collaborative Institutional Training Initiative (CITI) 11/2011-Present

WORK EXPERIENCE:

Medical Scientist/Clinical Research Coordinator
American Oncology Network Vista Oncology Division
420 McPhee Rd SW Olympia, WA 98502 05/2016-Present

CLINICAL RESEARCH EXPERIENCE:

- Ensures appropriate infrastructure to conduct clinical trials in accordance with the study protocol
- Applicable policies and regulation while ensuring participant safety.
- Collaborates with the Sponsor and Principal Investigators (PI) on assessment and implementation of highly complex trials for the research team.
- Prepares study start-up templates and documentation including contract review, budget negotiate, IRB submission, study-specific clinic orders and study calendars
- Serves as main point of contact with sponsors and keeps investigators informed about enrollment opportunities
- Screens and registers patients; ensures eligibility requirements are met
- Assures consent forms are completed correctly and in entirety and that the consent process is appropriately documented
- Proposes orders for study related clinic procedures such as blood draws, exams, infusions, and other procedures according to protocol requirements; coordinates with clinic, pharmacy staff and other clinical service areas to ensure proper documentation and timing of research-related procedures
- Attends clinic visits to update concomitant medications and adverse events and assure subject understanding of study requirements
- Responsible for the maintenance of study databases, including the abstraction and entry of data and CRF interpretation, potentially with data coordinator assistance
- Identifies procedural problems, communicates to the PI and research manager, and completes patient safety net reporting
- Manages Serious Adverse Event reporting to study sponsors and the IRB
- Assures adherence to research protocols and maintains protocol deviation documentation
- Collaborates with study monitors and responds to findings
- Creates and maintains patient tracking tools; communicates status to sponsors, investigators, management, and relevant departments
- Acts as a resource to physicians, investigators, other staff members, and other organizations regarding protocol procedures, data collection requirements and other study related operations
- Maintains EDC records timely
- Maintains study financial trackers and budget negotiation
- Keeps knowledge and skills current by completing mandated training and attending meetings with the study team, such as the monthly coordinator meeting
- Complete protocol specific nursing assessments for study participants with appropriate documentation in the medical record.
- Monitor lab results and outside medical records. Communicate clinically significant events to the PI and triage as necessary.
- Provide protocol specific nursing education to study participants, caregivers, and colleagues.

- Perform clinical procedures such as blood draws from central line catheters and peripheral sites; evaluation of skin in suspected graft vs. host disease including skin biopsies; and other procedures within RN scope of practice as necessary
- Administer medications, including study drugs, biologicals, according to protocol and within RN scope of practice.
- Assess patient and monitor for side effects to study drug with appropriate response including administration of PRN medications per protocol and, as necessary, consultation with PI or medical care team.

Trials List (partial):

Magnify CC-5013-NHL-008: A phase 3b randomized study of lenalidomide (CC-5013) plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma.

NILE-Trial 03-001: Noninvasive vs. Invasive Lung Evaluation

AVANA trial: A Randomized, Parallel, Double Blinded Study to Compare the Efficacy and Safety of FKB238 to Avastin® In 1st Line Treatment for Patients with Advanced/Recurrent Non-Squamous Non-Small Cell Lung Cancer in Combination of Paclitaxel and Carboplatin

UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab+TGR-12025 and TGR-1202 alone in Patients with Previously Treated Diffuse Large B-Cell Lymphoma

UTX-TGR-304: A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)

PANOVA-3: Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma

DIV-SCLC-301: A Two-Part, Open-Label, Randomized, Phase II/III Study of Dinutuximab and Irinotecan versus Irinotecan for Second Line Treatment of Subjects with Relapsed or Refractory Small Cell Lung Cancer

D419BR00008: Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma

MOR208C310: A Phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

INCMOR 0208-301: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to Rituximab Versus Lenalidomide in Addition to Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma Grade 1 to 3a or R/R Marginal Zone Lymphoma

Research Assistant
Clinical Research Center, Morehouse School of Medicine, Atlanta GA
Egleston, Children's Healthcare of Atlanta, Atlanta GA 02/2015-05/2016

Research Assistant
Department of Physiology, Morehouse School of Medicine, Atlanta GA 03/2014-12/2014

Research Assistant
Neuroscience Institute, Morehouse School of Medicine, Atlanta GA 07/2011-02/2014

PUBLICATIONS and SEMINAR:

1. Bian F, Simon RP, **Li Y**, David L, Wainwright J, Hall CL, Frankel M, Zhou A (2014) Nascent proteomes in peripheral blood mononuclear cells as a novel source for biomarker discovery in human stroke. Stroke. February 20: doi: 10.1161/STROKEAHA.113.004576 (PMCID: PMC3992918)
2. Fang Bian, Jayne Rice, Li Cao, **Yun Li,** and An Zhou. Distinct roles of polycomb group proteins and their associated proteins in neuronal cells and endocrinal cells. *Manuscript in Preparation*
3. An Zhou, Fang Bian, Li Cao, **Yun Li**, Michael Frankel, Jolita Wainwright, Roger Simon. Characterization of Multiple Blood Proteomes in African American Stroke Patients. *Manuscript in Preparation*
4. Li Cao, **Yun Li,** Roger Simon, Michael Frankel, Jolita Wainwright, and An Zhou, Distinct plasma proteomic variation between male and female African American stroke patients. *Manuscript in Preparation*
5. Immergluck LC, Laghaie E, Newman G, Malik AA, Ali F, Churchill VM, Thornton K, **Li Y**, Fareed S, Mohammed A, Stanley T, Leong T, Jerris RC. "Risk for Primary and Recurrent Community-Associated MRSA Skin & Soft Tissue Infections (SSTI): A Closer Look at The Role of Specific Bacterial Strains & Innate Host Response." Emory University Antibiotic Resistance Center Seminar. Atlanta, GA. August 19, 2015.

AWARDS and CONFERENCE:

MSM Presidential Scholarship The 100 club Scholarship
Morehouse School of Medicine, Atlanta GA 08/2015

MSM Epidemiology Scholar Award
Morehouse School of Medicine, Atlanta GA 08/2015

Antibiotic Resistance Seminar: National Priorities for Urgent Action
Emory University, Atlanta GA 08/2015

HELA Conference 20th
Morehouse School of Medicine, Atlanta GA 09/2015

COMPUTER and Other SKILLs:

- Language Skills: English and Chinese Bilingual
- Microsoft Office software: Word, Excel, Powerpoint, Image J, Photoshop
- SAS statistical software and Bioinformatics software for primer design, prediction of Protein structure, sequence homology analysis, and bioinformatics databases and other useful online tools.

REFERENCES:

- Joseph Ye, M.D., PhD, Head Physician and clinic owner. Vista Oncology Inc. PS Email josephy@vista-oncology.com Cell Phone: (360)480-3665
- Qing Song, M.D., PhD, Assistant Professor. Cardiovascular Research Institute, Morehouse School of Medicine qsong@msm.edu Office Phone: (404)-752-1845
- Shaojin You, MD, Ph.D, Director , Histo-Pathology Core Atlanta Research & Educational Foundation Atlanta VA Medical Center, Shaojin.You@va.gov or shaojinyou@yahoo.com Office Phone:404-321-6111 ext.2516 or 4190